08:00 , Jan 5, 1998 |  BC Week In Review  |  Company News

Gensia Automedics Inc., Gensia deal

GNSA transferred its medical products, including GenESA System, Feedback Controlled Heparin System and Brevibloc esmolol, a short-acting beta blocker, to its Automedics subsidiary. GNSA will receive milestones, royalties, and manufacturing payments. GNSA will incur a...
08:00 , Mar 24, 1997 |  BC Week In Review  |  Company News

Gensia, Sanofi Winthrop UK Ltd. sales and marketing update

GNSA appointed Sanofi exclusive distributor in the U.K. and Ireland of the cardiovascular drug Brevibloc (esmolol), a short acting beta-blocker used in surgery to treat tachycardia and hypertension and in cardiology to treat supraventricular tachyarrhythmias....
07:00 , Oct 11, 1993 |  BC Week In Review  |  Company News

Gensia Inc. sales and marketing update

GNSA signed an exclusive agreement with the pharmaceutical products division of Ohmeda Inc. under which GNSA will distribute and market Brevibloc, an acute care cardiovascular drug, in Europe. Brevibloc is an ultra-short-acting intravenous beta-blocker to...